Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors

NCT06320405 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT06320405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06320405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 21, 2024
Completion date
April 1, 2029
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, metastatic malignant solid neoplasm, recurrent malignant solid neoplasm, refractory malignant solid neoplasm